FY2026 Earnings Estimate for LENZ Issued By William Blair

LENZ Therapeutics, Inc. (NASDAQ:LENZ) – Stock analysts at William Blair issued their FY2026 earnings per share estimates for shares of LENZ Therapeutics in a research note issued to investors on Thursday, March 20th. William Blair analyst L. Hanbury-Brown forecasts that the company will post earnings per share of ($2.89) for the year. The consensus estimate for LENZ Therapeutics’ current full-year earnings is ($2.18) per share.

Several other equities analysts have also issued reports on LENZ. Citigroup lifted their price target on LENZ Therapeutics from $44.00 to $47.00 and gave the company a “buy” rating in a research note on Thursday. TD Cowen started coverage on LENZ Therapeutics in a research note on Tuesday, March 18th. They set a “buy” rating and a $60.00 target price for the company. Seven equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $41.67.

LENZ Therapeutics Price Performance

Shares of LENZ opened at $26.49 on Friday. The firm has a 50 day simple moving average of $24.15 and a two-hundred day simple moving average of $27.06. LENZ Therapeutics has a one year low of $14.42 and a one year high of $38.93. The company has a market cap of $728.50 million, a P/E ratio of -5.55 and a beta of 0.58.

LENZ Therapeutics (NASDAQ:LENZ) last posted its quarterly earnings results on Wednesday, March 19th. The company reported ($0.46) EPS for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.04).

Hedge Funds Weigh In On LENZ Therapeutics

Several large investors have recently modified their holdings of the business. Mirae Asset Global Investments Co. Ltd. bought a new position in LENZ Therapeutics during the 4th quarter worth $29,000. KLP Kapitalforvaltning AS acquired a new position in shares of LENZ Therapeutics in the fourth quarter worth approximately $46,000. Tower Research Capital LLC TRC lifted its stake in shares of LENZ Therapeutics by 162.3% in the fourth quarter. Tower Research Capital LLC TRC now owns 1,860 shares of the company’s stock worth $54,000 after acquiring an additional 1,151 shares during the period. Virtus ETF Advisers LLC bought a new stake in LENZ Therapeutics in the fourth quarter valued at approximately $67,000. Finally, SG Americas Securities LLC increased its position in LENZ Therapeutics by 20.7% during the 4th quarter. SG Americas Securities LLC now owns 5,458 shares of the company’s stock valued at $158,000 after purchasing an additional 935 shares during the period. Institutional investors own 54.32% of the company’s stock.

About LENZ Therapeutics

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.